Company intelligence / Profile preview

Cebix

San Diego (La Jolla), California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Cebix developed Ersatta (CBX129801), a PEGylated synthetic human C-peptide for treating diabetic complications. The company completed a Phase 2b trial in December 2014, but results showed Ersatta was "indistinguishable" from placebo, leading to the company's shutdown in early 2015.

Therapeutic areas: Endocrinology
Modalities: Peptides
Industry: Biotech

Drug pipeline

2 assets

C-peptide

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Cebix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cebix.

Explore the full profile